An interventional study of Community health worker intervention and Standard Care (in control arm) in Kidney Diseases and Chronic Kidney Diseases, sponsored by University of Colorado, Denver. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-24.
Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Kidney Diseases by University of Colorado, Denver — 3 open to participants now, 6 under way, none of them phase 3. Kidney Diseases · University of Colorado, Denver.
Among the 13 studies in Kidney Diseases by University of Colorado, Denver, this one has the largest planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2026, is one of 5 with no phase, and was the 11th registered.
970 studies on the registry are indexed under Kidney Diseases; 185 are open to participants now.
Browse Kidney Diseases studies →3 of the 13 studies in Kidney Diseases by University of Colorado, Denver are open now, in 1 country. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 22–40 · Women only · Healthy volunteers
University of Colorado, Denver · Sites in United States
Ages 18–80
By country, each count listing its studies:
Of the 131 Kidney Diseases studies recruiting now, 77 (59%) set no upper age limit and 34 (26%) stop at 75 or younger; 27 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 4 2
First in 2010; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 448 is above the median of 64 across 647 interventional studies indexed under Kidney Diseases.
Median enrollment 50 across the 11 interventional studies, 40 across the 2 observational. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.
Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.
1 of the studies in Kidney Diseases by University of Colorado, Denver that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06496542University of Colorado, DenverRenal Oxygen Consumption, Insulin Sensitivity, and Daily Caloric Restriction in ADPKD | 2027-08-01 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Kidney Diseases by University of Colorado, Denver, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overarching goal of this project is to refine and adapt previous work on the NAVIGATE-Kidney project for individuals with CKD. The investigators hypothesize that the multilevel NAVIGATE-Kidney program intervention will reduce the rate of central venous catheter use at KRT start (primary outcome), increase the rate of optimal KRT starts (secondary outcome), increase patient activation, and reduce decisional conflict (patient-centered outcomes) for individuals with advanced CKD. The project will have four (4) aims.
The overarching goal of this project is to reduce kidney health disparities faced by individuals with advanced kidney disease. The team developed Navigate-Kidney, a community health worker (CHW) intervention to improve clinical and person-centered outcomes for individuals with kidney failure receiving maintenance hemodialysis. The investigators now aim to test NAVIGATE-Kidney among individuals with advanced CKD stage 4. The investigators hypothesize that compared to standard care, the multilevel NAVIGATE-Kidney intervention will reduce the composite endpoint, defined as (1) time to transition to KRT and central venous catheter use or (2) death (primary outcome), increase the rate of optimal KRT starts and optimal KRT process measures (secondary clinical outcomes), increase patient activation, reduce social challenges, and reduce decisional conflict (patient-centered outcomes) for individuals with advanced CKD stage 4/5 (eGFR 15-29 mL/min/1.73m2). The investigators will also evaluate Navigate-Kidney implementation outcomes using the PRISM (Practical Robust Implementation and Sustainable Model) science framework and conduct an economic evaluation to inform policy change.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Arm Description: A CHW will provide support during visits every 2 weeks for 3 months (i.e., 6 visits during first 3 months) followed by monthly visits until 1 year of study participation and then quarterly visits until 2 years of study participation. The CHW Navigate-Kidney intervention includes 4 functions: (1) Build trust through understanding of health experience; (2) Address multilevel social and challenges to facilitate health system navigation; (3) Provide patient-centered education; and (4) Enhance self-management. To provide patient-centered education, the CHW will use a Decision Aid created for this intervention.
Behavioral: Community health worker intervention
Arm Description: Arm Description: Participants will receive standard medical care following diagnosis. This care will include educational materials developed that describe prevention of CKD progression, KRT options, and conservative management in English or Spanish
Behavioral: Standard Care (in control arm)
Community health worker support that includes building trust, addressing social challenges, providing patient-centered education, and enhancing self-management.
Participants receive standard care
Composite Outcome: Time Until Kidney Replacement Therapy (KRT) Start with Central Venous Catheter (CVC) Use or Death
Composite outcome of time until participants in each arm either 1) begin dialysis (either as first KRT method or as a subsequent preparatory step for transplant) with a central venous catheter (CVC)), or 2) die from all-cause mortality, whichever occurs first.
Time frame: From Baseline until End of Study, KRT Start, or Death, whichever occurs first (up to 5 years)
Rate of Central Venous Catheter (CVC) use at onset of Kidney Replacement Therapy (KRT) or Death
Rate of participants in each arm that either 1) "crash start" Kidney Replacement Therapy (KRT) via first starting dialysis with a Central Venous Catheter (CVC), or 2) die from all-cause mortality prior to starting any method of KRT, whichever occurs first.
Time frame: From Baseline until End of Study, KRT Start, or Death, whichever occurs first (up to 5 years)
Rate of Participants with Optimal Kidney Replacement Therapy (KRT) Start
Rate of patients with condition: "Optimal KRT start", a composite measure (defined by the CMS Kidney Care Choices (KCC) value-based payment model) that includes patients with any of the following: 1. Pre-emptive kidney transplant; 2. Home dialysis; and/or 3. In-center dialysis start with a functional arteriovenous fistula or graft.
Time frame: From Baseline until End of Study, KRT Start, or Death, whichever occurs first (up to 5 years)
Time to First Optimal Kidney Replacement Therapy (KRT) Process Measure Milestone
Optimal Kidney Replacement Therapy (KRT) start process measure milestones are defined as the following: (1) Endpoints for permanent vascular access: vascular mapping and surgical visit or referral; (2) Endpoints for kidney transplant: Initial transplant visit, undergoing work-up for waitlisting, and waitlisting; (3) Endpoints for home dialysis: Initial evaluation visit for home dialysis.
Time frame: From Baseline until End of Study, KRT Start, or Death, whichever occurs first (up to 5 years)
Change in Estimated Glomerular Filtration Rate eGFR
Measure of kidney function, reported in mg/dL. Scores of less than 15 may indicate kidney failure, while scores of 90 or higher indicate normal kidney function.
Time frame: Screening until End of Study or Death, whichever occurs first (up to 5 years)
Change in Decisional Conflict Scale (DCS) scores
Decisional Conflict Scale (DCS) is a 16-item tool that evaluates patient decisional conflict in 4 domains: informed, clarity, uncertainty, and support. Possible total scores range from 0 to 100, with higher scores indicating higher decisional conflict and worse outcomes.
Time frame: Baseline, Month 6, Month 12, Month 24
Change in Patient Activation (PAM-13) scores
Patient activation is measured with the Patient Activation Measure 13 (PAM-13), ranging in scores from 0 to 100. Higher scores are associated with improved behaviors related to the patient's self-management of their health and disease, and a better outcome.
Time frame: Baseline, Month 6, Month 12, Month 24
Change in Quality of Life, as measured by Patient-Reported Outcomes Measurement Information Systems' (PROMIS) Global Health Scale scores
The PROMIS Global Health Scale Version 1.2. is a 10-item tool that evaluates self-reported measures of patients' physical health and function. Possible scores range from 1-10, with higher scores indicating better health and function, and better outcomes.
Time frame: Baseline, Month 6, Month 12, Month 24
Change in Social Determinants of Health, as measured by AHC-HRSN Responses
The Accountable Health Communities (AHC) Health-Related Social Needs (HRSN) Screening Tool is a 10-item, tool that identifies health-related social needs (HRSNs) in patients in 5 domains: Housing Instability, Food Insecurity, Transportation Problems, Interpersonal Safety, and Utility Help needs. Each item is scored using a Yes/No response format. Yes answers indicate a positive screening for a patient need.
Time frame: Baseline, Month 6, Month 12, Month 24
Change in KRT knowledge as measured by the Rotterdam Renal Replacement Knowledge Test (R3K-T, 30 items)
The Rotterdam Renal Replacement Knowledge test (R3K-T) is a 30-item tool that assesses participant knowledge of renal replacement therapy. Possible scores range from 0 to 30, with higher scores indicating more correct answers and higher participant knowledge about therapy.
Time frame: Baseline, Month 6, Month 12, Month 24
Change in Medical Mistrust, as measured by the Medical Mistrust Index (MMI)
The Medical Mistrust Index (MMI) is an 11-item measure that evaluates participants' mistrust of health care organizations. The MMI items are scored on a 4-response Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree), with higher scores indicating more mistrust of healthcare organizations
Time frame: Baseline, Month 6, Month 12, Month 24
Dissemination and implementation RE-AIM outcomes for Navigate-Kidney
PRISM (Practical Robust Implementation and Sustainable Model) contextual factors will be used to assess dissemination and implementation outcomes. PRISM consists of 2 parts: 1) Key contextual factors that impact implementation 2) Implementation outcomes called RE-AIM (Reach-Effectiveness-Adoption-Implementation-Maintenance). Qualitative interviews with community health workers and participants assigned to the NAVIGATE-Kidney intervention arm will be conducted.
Time frame: Baseline up to End of Study (up to 5 Years)
Economic Evaluation Outcomes
Estimations of the cost of implementing and sustaining the intervention, and analysis to determine the economic value of NAVIGATE-kidney by calculating the incremental cost-effectiveness ratio (ICER) compared to standard care.
Time frame: Baseline up to End of Study (up to 5 Years)
Plan to share: Yes — Limited data sets will be shared at end of study via an NIDDK registry: NIDDK-CR, in accordance with NIDDK data sharing policies.
Time frame: Within 12 months of Primary Completion Date, ongoing.
Data sharing details ↗ · repository.niddk.nih.gov
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for May 2029, 37 months after the start.
Of 127 non-industry interventional studies with no phase under Kidney Diseases, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 52. This study's planned 37 months is close to that.
Counting every sponsor, half of 147 studies reached it within 34 months; a quarter within 13 and three quarters within 49.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Colorado, Denver →